As fatty acid amide hydrolase (FAAH) catalyzes the metabolism of the eCB anandamide, treatment with the FAAH inhibitor URB-597 improved performance in fragile X syndrome gene fmr1 KO mice, possibly via the anxiolytic effects of FAAH inhibition. Here, FAAH is linked to fragile X syndrome.